Iberdomide and Daratumumab after stem cell transplant for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests two medicines, iberdomide and daratumumab, given as maintenance therapy after an autologous stem cell transplant. It is for people with multiple myeloma who still have small amounts of cancer cells detected after transplant and who have already been treated with a daratumumab-containing regimen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma and have already received at least 3 cycles of a treatment that included daratumumab, and your cancer had at least a partial response to that treatment.
- You must have completed an autologous stem cell transplant between 90 and 150 days ago, and your cancer has not gotten worse since then.
- A test done 90 to 150 days after transplant must show that you still have minimal residual disease (MRD positive) using a sensitive method.
- You must be at least 18 years old and have an ECOG performance status of 0, 1, or 2 (meaning you are up and active at least half the day).
- Your blood counts, kidney function, and liver function must meet minimum levels, and any side effects from the transplant must have mostly gone away.
- Sexually active men and women must agree to use effective birth control during and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
This trial tests a personalized approach to maintenance therapy for people with multiple myeloma who have already had a stem cell transplant. Your treatment plan may be adjusted based on how well your cancer responds and on certain risk factors, with the goal of keeping you in remission longer.
This trial tests whether a new drug called elranatamab combined with lenalidomide works better than the standard daratumumab/lenalidomide combination as maintenance therapy after a stem cell transplant for newly diagnosed myeloma.
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
This trial tests a drug called elranatamab to keep multiple myeloma from coming back after an autologous stem cell transplant. It is for people who still have small amounts of cancer cells detectable after transplant.
This Phase 2 study tests whether adding isatuximab and lenalidomide after an autologous stem cell transplant can keep multiple myeloma from coming back when tests show leftover (minimal) disease. If it works, it may improve how long you stay in response.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.